Is QTTB's EPS showing recovery signs for 2024?

**QTTB's EPS does not appear to be showing recovery signs for 2024.** The company's financial results for the quarter ended December 31, 2024, reveal a continued decline in EPS, with a reported adjusted loss of $1.16 per share. This is higher than the same quarter last year, when the company reported EPS of $-5.04. The mean expectation of four analysts for the quarter was for a loss of $1.51 per share, indicating a worsening outlook compared to the previous quarter's expectations. 1. **Economic Performance**: The company's reported revenue was zero, which is a concerning indicator of its inability to generate income to cover its expenses and losses. This is consistent with the previous quarter's performance, where revenue was also reported to be zero. 2. **Comparative Analysis**: When compared to the previous quarter's EPS of $-14.95, the current quarter's EPS of $-1.16 represents an improvement in terms of loss magnitude. However, this does not necessarily indicate recovery, as the company's EPS remains in the negative territory. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |QTTB|QTTB.O|Q32 Bio|2024 Q1|68.09475806451613|-6.33|186| |QTTB|QTTB.O|Q32 Bio|2024 Q2|91.49191132414619|-1.42|186| |QTTB|QTTB.O|Q32 Bio|2024 Q3|96.39684106614017|-1.46|186| 3. **Analyst Expectations and Ratings**: - The mean earnings estimate of analysts had fallen by about 7.2% in the last three months, indicating a downward revision in expectations. - In the last 30 days, there have been no earnings estimate revisions by analysts covering the company, suggesting a lack of positive outlook changes. - The current average analyst rating on the shares is "buy," with a breakdown of recommendations that includes no "hold" ratings, which may reflect a cautious stance from analysts regarding the stock's potential for recovery. 4. **Stock Performance and Market Sentiment**: - Q32 Bio Inc shares had fallen by 40.1% this quarter, which could be indicative of market disappointment or concerns about the company's financial health and recovery prospects. - Wall Street's median 12-month price target for Q32 Bio Inc is $11.00, which is significantly lower than the current trading price, suggesting a bearish sentiment among analysts regarding the stock's future performance. In conclusion, while there is a slight improvement in the magnitude of the loss, the fact that QTTB's EPS remains negative and revenue is reported as zero indicates that the company is still facing significant challenges. The absence of positive earnings estimate revisions, the lack of revenue generation, and the bearish analyst price targets suggest that QTTB's EPS does not show signs of recovery for 2024.